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Chemotherapy along with radiotherapy is a major treatment of
medical oncology. Despite their therapeutic effects achieving
local tumor control and in many cases controlling metastasis,
both approaches can produce serious adverse effects to
normal tissues either immediately or during the long term after
treatment. Thus, their related toxicity frequently outweigh
clinical benefits and worsen patient’s quality of life.1,2
Regardless of the high incidence of cancer therapy-
associated adverse reactions (e.g., hepato, hemato and
cardio toxicities) and their significant impact on morbidity,
mortality and health economics; as far as we know, there are
no standard, clinically approved, effective agents that could
improve the therapeutic index of chemo and radiotherapy,
controlling these devastating side effects in patients under-
going anti-tumoral treatments.1,2 Therefore, the development
of pharmacological approaches to effectively prevent conven-
tional cancer therapy-induced toxicity is of utmost importance.
In this line, there are several reports demonstrating that
histamine could be a promising selective pharmacological
agent for the protection of radio-sensitive healthy tissues
against ionizing radiation-induced adverse effects. Histamine
administration was safely used in different radiobiological
experimental models and produced a marked preservation of
gamma radiation impaired morphological and functional
characteristics of small intestine, salivary glands and bone
marrow.3–5 Histamine has also demonstrated efficacy in
ameliorating boron neutron capture therapy-induced mucosi-
tis in an oral pre-cancer model.6
It is important to highlight that histamine exerts anti-
proliferative effects in different experimental models of human
breast cancer, melanoma and cholangiocarcinoma.7,8 Even
more, histamine potentiates radiation-induced anti-neoplastic
effects in human breast cancer cells. Recent results demon-
strated that the combined treatment of histamine and gamma
radiation leads to enhanced apoptosis, senescence and DNA
damage, modulating oxidative stress. In addition, the in vivo
treatment with histamine significantly reduced the size and the
increased exponential doubling time of irradiated triple-
negative breast tumors (TNBT) induced in nude mice with
MDA-MB-231 cells.9
Breast cancer is the most common cause of cancer death in
women worldwide. The anthracycline doxorubicin is one of the
standards of care in TNBT, which accounts for 15–20% of all
breast cancers, and is characterized by poor prognosis.10 In
addition, doxorubicin is a highly effective anti-neoplastic
agent, being one of the most commonly systemic treatments
to improve other several adult and pediatric cancers, including
both hematological and solid tumors.2 Unfortunately, the
clinical efficacy of doxorubicin is hindered by dose-related
adverse effects that could be acute or become evident years
after finalizing chemotherapy.2 Doxorubicin-induced toxicities
include hematopoietic suppression, hepatotoxicity and life-
threatening cardiotoxicity, being the latter the most serious
doxorubicin-related side effect.2,11
Numerous doxorubicin-induced cytotoxic mechanisms
have been identified. Like gamma radiation, doxorubicin in-
duces in part its anti-proliferative effects by augmenting re-
active oxygen species and inducing DNA damage.2 Hence,
oxidative stress has a key role in both doxorubicin-induced
cardiac and hepatic toxicities.2,11 Unfortunately, there are no
clinically effective therapeutics for doxorubicin-associated
cardio or hepatotoxicity.
Recently, Martinel Lamas et al.12 demonstrated the cyto-
protective capacity of histamine against doxorubicin-induced
injury of normal tissues in different pre-clinical experimental
models. The authors evaluated the effect of histamine admin-
istration on doxorubicin-induced hepatic and cardiac toxicity in
rat and mouse species and in a TNBT-bearing mouse model,
exploring histopathological, oxidative stress and biochemical
parameters.12
This study,12 shows that pre-treatment with histamine
prevented doxorubicin-induced cardiac toxicity, producing a
significant preservation of the myocardium integrity of both
Sprague–Dawley rats and Balb/c mice, more likely through a
reduction of doxorubicin-induced oxidative stress and
DNA damage. Histamine significantly alleviated histological
damage, reducing lipid peroxidation, serum creatine kinase-
myocardial band activity and expression of DNA double-strand
breaksmarker γH2AX. Histamine also blocked the decrease in
heart weight, whereas it enhanced thiol levels in doxorubicin-
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treated animals (Figure 1). These findings are in agreement
with previous works, which demonstrated the protective effect
of histamine on radiation-induced damage through the mod-
ulation of antioxidant enzymes and the reduction of genotoxic
damage.3,4
To further support the protective role of histamine, it was
recently reported that histamine deficiency aggravated myo-
cardial damage in acute myocardial infarction through im-
paired macrophage infiltration and increased apoptosis of
cardiomyocytes.13
In their study,12 the authors also showed that histamine
administration prevented doxorubicin-induced hepatotoxicity,
which is another common complication of doxorubicin chemo-
therapy.11 Pre-treatment with histamine mitigated hepatocyte
apoptosis and liver atrophy in an oxidative stress setting
(Figure 1). In addition, histamine blocked doxorubicin-induced
reduction of Kupffer cells, long-lived liver macrophages, in
accordance with the study by Deng et al.13 that indicated the
importance of histamine in modulating the infiltration and
differentiation of macrophages in damaged areas, which
contribute to tissue healing. Also, other authors reported that
histamine effectively protects liver against I/R-induced histo-
logic, functional and oxidative damage.8
The combination therapy with doxorubicin and histamine
was further evaluated in TNBT to verify whether it could
compromise chemotherapeutic efficacy. Histamine revealed
synergistic anti-tumor activity when administered with
doxorubicin both in vitro and in vivo models of TNBT,
enhancing doxorubicin-induced apoptosis and DNA
damage (Figure 1). Remarkably, the mice bearing TNBT
further verified the selective cardio and hepatoprotective
action of histamine.
On the basis of these findings (Figure 1), Martinel Lamas
et al.12 postulate that histamine exhibits chemoprotective
effects against doxorubicin-induced cytotoxic and oxidative
damage in heart and liver, without compromising the
anti-tumor activity of doxorubicin. Thereby, the combined
use of histamine with doxorubicin could be an attractive
strategy to improve the therapeutic ratio of doxorubicin
chemotherapy.
In the last decade, numerous clinical trials evaluated the
effects of the combination of immunotherapy with interleukin
(IL)-2 and histamine dihydrochloride (subcutaneous), for the
potential treatment of metastatic melanoma, acute myelogen-
ous leukemia and renal cell carcinoma.14 In agreement with
Martinel Lamas et al.12 histamine dihydrochloride displayed
enhanced anti-tumor activity when administered with IL-2 in
the treatment of diverse types of tumors and has the potential
to prevent oxidative stress-induced damage, preserving
immune cells such as natural killer and T-cells.14
The presented evidences suggest that the promising
combination therapeutic strategy with doxorubicin and
histamine could be easily translated into clinical practice.
Furthermore, a multifunctional targeting delivery system for
doxorubicin that includes histamine in the micelle has been
recently reported. This system facilitated the anti-tumor
efficacy of doxorubicin in multidrug resistant breast cancer
cells, through the enhancement of doxorubicin release in the
tumor site and reducing its heart's uptake.15 Thus, the
combination therapy based on doxorubicin-loading systems
that include histamine could further improve therapeutic
outcomes of TNBT.
In conclusion, the study by Martinel Lamas et al.12 suggests
that cancer combination therapy with histamine could
enhance clinical efficacy by reducing toxicity and potentiating
anti-tumor activity and thereby improving patients' health and
quality of life.
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Figure 1 Histamine (HA) selective cytoprotective effect against doxorubicin (DOX) toxicity. HA blocked DOX-induced cytotoxicity in liver and heart mainly through the
modulation of ROS and reducing DNA damage. In tumor cells, HA synergized DOX effects, inhibiting proliferation, augmenting DNA damage and apoptosis. Red arrows indicate
DOX effects; blue dashes indicate HA blockade of DOX effects, and violet arrows indicate HA potentiation of DOX effects
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